Announcements
- Terns Pharmaceuticals to Participate in UBS Obesity Therapeutics Day
- Terns Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate Updates
- Terns Pharmaceuticals Announces Leadership Changes
- Terns Pharmaceuticals to Participate in The Citizens JMP Life Sciences Conference 2024
- Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)
- Terns Pharmaceuticals Announces Data from Ongoing Phase 1 Pharmacokinetic Study of Allosteric BCR-ABL Inhibitor TERN-701 in Adult Healthy Volunteers and Highlights Potential for Competitive Differentiation
- Terns Pharmaceuticals Appoints Melita Sun Jung as Chief Business Officer
- Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates
- Terns Pharmaceuticals Announces Orphan Drug Designation Granted to TERN-701 for the Treatment of Chronic Myeloid Leukemia
- Terns Pharmaceuticals to Participate in Upcoming March Investor Conferences
More ▼
Key statistics
On Friday, Terns Pharmaceuticals Inc (430:STU) closed at 5.40, 74.47% above the 52 week low of 3.10 set on Nov 13, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 5.60 |
---|---|
High | 5.60 |
Low | 5.40 |
Bid | 5.40 |
Offer | 5.55 |
Previous close | 5.50 |
Average volume | 120.00 |
---|---|
Shares outstanding | 64.67m |
Free float | 63.52m |
P/E (TTM) | -- |
Market cap | 381.58m USD |
EPS (TTM) | -1.26 USD |
Data delayed at least 15 minutes, as of May 17 2024.
More ▼